- Conditions
- Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis, Letrozole, Questionnaire Administration, Tamoxifen Citrate
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 521
- States / cities
- Mobile, Alabama • Fort Smith, Arkansas • Antioch, California + 355 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 351
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ductal Carcinoma in Situ, Invasive Ductal Carcinoma of Female Breast
- Interventions
- stereotactic body radiation therapy
- Radiation
- Lead sponsor
- RPCR, Inc.
- Other
- Eligibility
- 50 Years to 100 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Stuart, Florida • Tampa, Florida
- Conditions
- Breast Cancer, Invasive Breast Carcinoma
- Interventions
- Aerobic Exercise Intervention, Resistance Exercise Intervention, Exercise Intervention: Digital copies and outline of sessions, Questionnaire Administration, Quality-of-Life Assessment
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
- Interventions
- Fulvestrant, Repotrectinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- DCIS, Invasive Breast Cancer
- Interventions
- Stool sample, Skin Swab Sample
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Inflammatory Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Tubular Ductal Breast Carcinoma
- Interventions
- External beam radiation therapy
- Radiation
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • Salt Lake City, Utah
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer, Hormone Receptor Negative Breast Cancer, Metastatic Breast Cancer
- Interventions
- Brachyury-TRICOM, Entinostat, M7824, Ado-trastuzumab emtansine
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer
- Interventions
- Palbociclib, Bazedoxifene
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- HER2-negative Breast Cancer
- Interventions
- Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF
- Drug · Diagnostic Test
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 43
- States / cities
- Colton, California • Miami Beach, Florida • Orlando, Florida + 34 more
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Positive Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Carboplatin, Docetaxel, Fulvestrant, Pertuzumab, Quality-of-Life Assessment, Ribociclib, Trastuzumab, Tucatinib
- Drug · Biological · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Metastatic Breast Cancer, Leptomeningeal Disease
- Interventions
- High-dose Methotrexate (8 gm/m2; HD-MTX)
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • St Louis, Missouri • Winston-Salem, North Carolina
- Conditions
- Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
- Interventions
- Axillary Lymph Node Dissection, Enzalutamide, Laboratory Biomarker Analysis, Lymph Node Biopsy, Paclitaxel, Therapeutic Conventional Surgery
- Procedure · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Magnetic Resonance Imaging (MRI), Magnetic Resonance Spectroscopy (MRS)
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, Anastrozole, Everolimus, Placebo - Anastrozole, Placebo - Everolimus
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 223
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 150 more
- Conditions
- Breast Cancer
- Interventions
- Transcutaneous vagus nerve and acupuncture point stimulation
- Device
- Lead sponsor
- The Healing Consciousness Foundation
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Meadowbrook, Pennsylvania
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma of No Special Type
- Interventions
- Biospecimen Collection, Letrozole, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Breast Fibrocystic Change, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Interventions
- Abemaciclib, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast Carcinoma
- Interventions
- Azacitidine
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
- Interventions
- zoledronic acid, laboratory biomarker analysis, therapeutic conventional surgery
- Drug · Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Invasive Breast Carcinoma
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Cancer
- Interventions
- gene expression analysis, mutation analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, medical chart review, quality-of-life assessment
- Genetic · Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 20 Years and older · Female only
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Duarte, California • Pasadena, California
- Conditions
- Breast Cancer
- Interventions
- IORT
- Radiation
- Lead sponsor
- Mount Carmel Health System
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
- Interventions
- Trastuzumab deruxtecan, Durvalumab
- Drug
- Lead sponsor
- Filipa Lynce, MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Houston, Texas